0001178913-18-000718.txt : 20180228
0001178913-18-000718.hdr.sgml : 20180228
20180228160514
ACCESSION NUMBER: 0001178913-18-000718
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180227
FILED AS OF DATE: 20180228
DATE AS OF CHANGE: 20180228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Elliott Russell P.
CENTRAL INDEX KEY: 0001727807
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 18651091
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER NAME:
FORMER CONFORMED NAME: Russell Elliot
DATE OF NAME CHANGE: 20180112
FORMER NAME:
FORMER CONFORMED NAME: Elliot Russel
DATE OF NAME CHANGE: 20180110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
zk1821305.xml
OWNERSHIP DOCUMENT
X0306
4
2018-02-27
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001727807
Elliott Russell P.
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
REHOVOT
L3
7670402
ISRAEL
0
1
0
0
VP Drug Development
Ordinary Shares
2018-02-27
4
A
0
8750
0.00
A
13685
D
Options
6.35
2018-02-27
4
A
0
26250
6.35
A
2028-02-27
Ordinary Shares
26250
26250
D
This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
Each option represents a contingent right to purchase one ordinary share of the issuer.
The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
/s/ Ilan Hadar as attorney-in-fact for Russell Elliott
2018-02-28